Stay updated on Glycine Supplement for Severe COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Glycine Supplement for Severe COVID-19 Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    An NIH announcement about a terminology transition was removed from the page, while the 403 error remained.
    Difference
    1%
    Check dated 2026-11-08T13:40:09.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:54:43.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A sitewide notice announces NIH website updates and a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T15:44:41.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the error page.
    Difference
    0.2%
    Check dated 2026-10-18T22:01:18.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T22:08:57.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record with a generic error screen. This indicates the page is currently inaccessible.
    Difference
    22%
    Check dated 2026-09-20T19:54:57.000Z thumbnail image

Stay in the know with updates to Glycine Supplement for Severe COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.